Soon-Shiong Leads $11.3 Million First Close at PDS Biotech

PDS Biotech said on September 14, 2026 that it completed an initial closing of a private placement of up to $22.3 million, raising $11.3 million in gross proceeds in a transaction led by NantWorks founder Dr. Patrick Soon-Shiong, who joins the company's board of directors.

PDS Biotech (PDSB) said on Monday it has completed an initial closing of a private investment in public equity financing of up to $22.3 million, taking in $11.3 million of gross proceeds at the first close. The transaction was led by Dr. Patrick Soon-Shiong, founder of NantWorks, who is joining the Princeton, New Jersey company's board of directors.

A PIPE — private investment in public equity — is a share sale negotiated directly with a small group of investors rather than through a broadly marketed public offering. For a small-cap developer, it is usually the fastest route to cash, and it is almost always priced at a level that dilutes existing holders. That trade-off is the immediate tension in Monday's announcement: new money and a marquee backer on one side, a larger share count on the other.

The money that has arrived, and the money that has not

The structure matters. PDS Biotech has raised $11.3 million now; the remaining $11.0 million of the headline $22.3 million figure is contingent, not banked. A tranche structure of this kind is common when a financing is tied to conditions still to be satisfied, and investors reading the release should treat the first number as cash and the second as an option.

That distinction shapes any runway arithmetic. Only the $11.3 million can be counted against current operating spend. Whether the balance follows, and on what timetable, is the single most consequential unanswered question in the announcement, and the company did not provide terms beyond the closing amounts in its statement, reported by Business Insider Markets.

Why the market read it as dilution first

The tape was unimpressed. PDS Biotech was quoted at 0.27 as of 15:27 GMT on September 14, down 7.77% from the previous close of 0.29, with a day range of 0.26 to 0.29. That is a stock trading below the one-dollar mark, which is the zone where financings become both more necessary and more expensive: the lower the share price, the more shares a given dollar amount buys, and the heavier the dilution per dollar raised.

Context helps explain part of the move but not all of it. The broad market was soft on the day. The S&P 500 tracker (SPY) was at $759.78, off 0.59%; the Nasdaq 100 tracker (QQQ) was at $707.61, down 1.02%; and the Dow tracker (DIA) stood at $524.14, down 0.31%. A 7.77% decline in a sub-dollar biotech on a day when large-cap tech fell about a percent is a stock-specific reaction, not a beta move. Micro-cap developers routinely sell off on financing news even when the capital is essential, because holders can price the new shares faster than they can price the science.

What a Soon-Shiong board seat changes

The strategic content of the announcement is the investor, not the amount. Soon-Shiong is the founder of NantWorks, and he is not simply writing a check here — he led the transaction and is taking a seat on the board. That is a different signal from an anonymous institutional allocation from a healthcare crossover fund.

Three things typically follow from a lead investor who also takes governance rights:

Information asymmetry works in shareholders' favor, eventually. A lead investor with board access has done diligence that public holders cannot replicate. Participation at scale is a statement about the pipeline's perceived value.
Follow-on capital becomes more plausible. An anchor with deep pockets and an existing position is the natural buyer in a second tranche or a future round, which lowers the risk that the company has to raise on distressed terms from the open market.
Strategic optionality widens. A founder-operator in the life sciences brings potential partnerships, manufacturing relationships and clinical networks. None of that is promised in the release, but it is why boards of small developers court investors of this profile.

The counterweight is governance concentration. A single lead investor with a board seat has influence over financing structure, strategic direction and any future sale process that ordinary shareholders do not. That is the price of the endorsement.

The runway question shareholders should press on

A single lead investor with a board seat has influence over financing structure, strategic direction and any future sale process that ordinary shareholders do not.

PDS Biotech did not, in the announcement, quantify how far the new capital extends its cash position. For a clinical-stage company, that is the number that determines everything else: how many trial milestones can be funded before the next raise, and whether the company negotiates its next financing from a position of strength or necessity.

Useful illustrative framing, using only the disclosed amounts: the $11.3 million now in hand represents roughly half of the maximum $22.3 million contemplated, leaving $11.0 million still to be closed. If the balance arrives, the company roughly doubles the cash this transaction delivers. If it does not, the runway calculation halves. This is arithmetic on the disclosed figures, not a company forecast.

What to watch from here

The near-term checkpoints are procedural and will show up in regulatory filings rather than press releases. Watch for the pricing terms and share count attached to the first tranche, since that fixes the dilution actually incurred. Watch for the conditions governing the second closing and its deadline. Watch for a stated cash-runway date in the next quarterly report, which will convert the financing into a timeline readers can measure clinical progress against.

And watch the stock's behavior once the initial selling pressure clears. Financing-day weakness in micro-cap biotech frequently reflects arbitrage and repositioning rather than a verdict on the asset. The more durable signal is whether a lead investor of Soon-Shiong's standing draws other capital in behind him at the second close.

Key facts

Initial closing proceeds: $11.3 million gross
Total PIPE size: Up to $22.3 million
Lead investor: Dr. Patrick Soon-Shiong, founder of NantWorks; joins the board
PDSB share price: 0.27, -7.77%, as of 15:27 GMT Sept 14, 2026

Frequently asked questions

How much did PDS Biotech actually raise?

PDS Biotech received $11.3 million in gross proceeds at the initial closing of the transaction. The financing is structured for up to $22.3 million in total, meaning the remaining portion has not yet been received. Only the $11.3 million should be treated as capital currently in hand; the balance is contingent on the terms of a further closing.

What is a PIPE financing?

A PIPE, or private investment in public equity, is a sale of shares by a publicly listed company directly to a selected group of investors rather than through a broadly marketed public offering. It is faster and cheaper to execute than a registered offering, but it is typically priced at a level that dilutes existing shareholders by increasing the total share count.

Who is Patrick Soon-Shiong and what is his role here?

Dr. Patrick Soon-Shiong is the founder of NantWorks. He led the PDS Biotech private placement and is being appointed to the company's board of directors. Leading a financing and taking a board seat gives an investor both a significant economic stake and governance influence over strategy, future capital raises and any potential transaction.

How did PDS Biotech shares react?

PDS Biotech was quoted at 0.27, down 7.77% from the prior close of 0.29, as of 15:27 GMT on September 14, 2026, with an intraday range of 0.26 to 0.29. Broader markets were also lower that day, with the Nasdaq 100 tracker off 1.02% and the S&P 500 tracker down 0.59%, but the decline in PDSB was company-specific.

Why do biotech stocks often fall on financing news?

New shares issued in a financing increase the total share count, reducing each existing holder's proportional ownership and earnings claim. For companies trading at low share prices, a given dollar amount buys more shares, so dilution per dollar raised is heavier. Investors can price that dilution immediately, while the value of the research the money funds takes years to become visible.

What does the financing say about PDS Biotech's cash runway?

The company did not quantify a runway extension in its announcement. Investors will need the next quarterly filing to see a stated cash position and the pricing terms of the shares issued. The key variable is whether the roughly $11.0 million still outstanding under the up-to-$22.3 million structure closes, which would roughly double the cash the deal delivers.

Sources

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors — Business Insider Markets

Photo: Edward Jenner · Pexels Licence — source